TWI630213B - 用於純化重組型惡性瘧原蟲（ｐｌａｓｍｏｄｉｕｍ ｆａｌｃｉｐａｒｕｍ）環孢子體蛋白質之方法 - Google Patents
用於純化重組型惡性瘧原蟲（ｐｌａｓｍｏｄｉｕｍ ｆａｌｃｉｐａｒｕｍ）環孢子體蛋白質之方法 Download PDFInfo
- Publication number
- TWI630213B TWI630213B TW102115278A TW102115278A TWI630213B TW I630213 B TWI630213 B TW I630213B TW 102115278 A TW102115278 A TW 102115278A TW 102115278 A TW102115278 A TW 102115278A TW I630213 B TWI630213 B TW I630213B
- Authority
- TW
- Taiwan
- Prior art keywords
- rcsp
- days
- protein
- pseudomonas
- stable liquid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 389
- 230000008569 process Effects 0.000 title description 45
- 101900205473 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 274
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 263
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 99
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 141
- 239000004475 Arginine Substances 0.000 claims description 117
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 117
- 239000000178 monomer Substances 0.000 claims description 107
- 239000000872 buffer Substances 0.000 claims description 99
- 239000000539 dimer Substances 0.000 claims description 97
- 238000000746 purification Methods 0.000 claims description 94
- 238000000926 separation method Methods 0.000 claims description 88
- 239000006166 lysate Substances 0.000 claims description 86
- 230000009467 reduction Effects 0.000 claims description 84
- 230000001580 bacterial effect Effects 0.000 claims description 81
- 229940063675 spermine Drugs 0.000 claims description 71
- 238000002360 preparation method Methods 0.000 claims description 69
- 241000589516 Pseudomonas Species 0.000 claims description 67
- 108010036949 Cyclosporine Proteins 0.000 claims description 64
- 238000004587 chromatography analysis Methods 0.000 claims description 64
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 63
- 229930105110 Cyclosporin A Natural products 0.000 claims description 63
- 239000013592 cell lysate Substances 0.000 claims description 63
- 229960001265 ciclosporin Drugs 0.000 claims description 63
- 229930182912 cyclosporin Natural products 0.000 claims description 63
- 239000012669 liquid formulation Substances 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 51
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 33
- 230000028327 secretion Effects 0.000 claims description 33
- 241000894007 species Species 0.000 claims description 31
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 230000036425 denaturation Effects 0.000 claims description 20
- 238000004925 denaturation Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 20
- 229910052586 apatite Inorganic materials 0.000 claims description 19
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 19
- 238000005571 anion exchange chromatography Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 239000007857 degradation product Substances 0.000 claims description 15
- 238000011026 diafiltration Methods 0.000 claims description 13
- 239000012537 formulation buffer Substances 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 238000012434 mixed-mode chromatography Methods 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 6
- 101710117490 Circumsporozoite protein Proteins 0.000 claims 2
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 claims 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 244
- 210000004027 cell Anatomy 0.000 description 221
- 238000004458 analytical method Methods 0.000 description 137
- 108090000765 processed proteins & peptides Proteins 0.000 description 133
- 229960003121 arginine Drugs 0.000 description 114
- 102000004196 processed proteins & peptides Human genes 0.000 description 109
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 100
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 96
- 238000006722 reduction reaction Methods 0.000 description 93
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 75
- 239000002953 phosphate buffered saline Substances 0.000 description 75
- 230000002829 reductive effect Effects 0.000 description 60
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 58
- 238000004007 reversed phase HPLC Methods 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 54
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 54
- 239000000523 sample Substances 0.000 description 53
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 50
- 238000005119 centrifugation Methods 0.000 description 49
- 235000018417 cysteine Nutrition 0.000 description 49
- 239000004202 carbamide Substances 0.000 description 48
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 48
- 239000003638 chemical reducing agent Substances 0.000 description 44
- 239000000463 material Substances 0.000 description 44
- 239000003795 chemical substances by application Substances 0.000 description 38
- 230000015556 catabolic process Effects 0.000 description 37
- 238000006731 degradation reaction Methods 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 34
- 239000000284 extract Substances 0.000 description 34
- 241000589540 Pseudomonas fluorescens Species 0.000 description 33
- 238000000855 fermentation Methods 0.000 description 33
- 230000004151 fermentation Effects 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 32
- 238000001914 filtration Methods 0.000 description 32
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 29
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 26
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 26
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- 239000007983 Tris buffer Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 239000010408 film Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 210000004899 c-terminal region Anatomy 0.000 description 22
- 230000006378 damage Effects 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 21
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 238000010257 thawing Methods 0.000 description 20
- 210000004897 n-terminal region Anatomy 0.000 description 19
- 238000011084 recovery Methods 0.000 description 19
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- -1 acetamylcysteine Chemical compound 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 238000000605 extraction Methods 0.000 description 18
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 18
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 18
- 230000029936 alkylation Effects 0.000 description 17
- 238000005804 alkylation reaction Methods 0.000 description 17
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 17
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 17
- 235000011130 ammonium sulphate Nutrition 0.000 description 17
- 238000000533 capillary isoelectric focusing Methods 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- 239000011347 resin Substances 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 238000012510 peptide mapping method Methods 0.000 description 16
- 238000001228 spectrum Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 15
- 238000006471 dimerization reaction Methods 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 238000007710 freezing Methods 0.000 description 15
- 230000008014 freezing Effects 0.000 description 15
- 238000011068 loading method Methods 0.000 description 15
- 238000001556 precipitation Methods 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000035195 Peptidases Human genes 0.000 description 13
- 239000004365 Protease Substances 0.000 description 13
- 108090000631 Trypsin Proteins 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 13
- 230000004520 agglutination Effects 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 239000012535 impurity Substances 0.000 description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 description 13
- 238000012423 maintenance Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 235000010755 mineral Nutrition 0.000 description 13
- 239000011707 mineral Substances 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- 239000013636 protein dimer Substances 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000012588 trypsin Substances 0.000 description 13
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 12
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 12
- 239000000919 ceramic Substances 0.000 description 12
- 238000002983 circular dichroism Methods 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 229920000669 heparin Polymers 0.000 description 11
- 229960002897 heparin Drugs 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 10
- 108010024636 Glutathione Proteins 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 10
- 230000017854 proteolysis Effects 0.000 description 10
- 230000003248 secreting effect Effects 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 9
- 241000588769 Proteus <enterobacteria> Species 0.000 description 9
- 229960003589 arginine hydrochloride Drugs 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 101150109249 lacI gene Proteins 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 108010016626 Dipeptides Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 238000002507 cathodic stripping potentiometry Methods 0.000 description 8
- 238000009295 crossflow filtration Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012531 culture fluid Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000013315 hypercross-linked polymer Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 108010067372 Pancreatic elastase Proteins 0.000 description 6
- 102000016387 Pancreatic elastase Human genes 0.000 description 6
- 241000224016 Plasmodium Species 0.000 description 6
- 241000192142 Proteobacteria Species 0.000 description 6
- 238000001142 circular dichroism spectrum Methods 0.000 description 6
- 238000011118 depth filtration Methods 0.000 description 6
- 230000006334 disulfide bridging Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 235000006109 methionine Nutrition 0.000 description 6
- 238000001471 micro-filtration Methods 0.000 description 6
- 238000000569 multi-angle light scattering Methods 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 238000012855 HCP-ELISA Methods 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- 238000011021 bench scale process Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 238000005352 clarification Methods 0.000 description 5
- 150000001944 cysteine derivatives Chemical class 0.000 description 5
- 230000006240 deamidation Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 238000005374 membrane filtration Methods 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 230000002572 peristaltic effect Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 101150116440 pyrF gene Proteins 0.000 description 5
- 229940043131 pyroglutamate Drugs 0.000 description 5
- 239000012925 reference material Substances 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 4
- 201000001718 Roberts syndrome Diseases 0.000 description 4
- 208000012474 Roberts-SC phocomelia syndrome Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DGMOQCHIPOPXEK-UHFFFAOYSA-N Spermic acid 2 Chemical compound OC(=O)CCNCCCCNCCC(O)=O DGMOQCHIPOPXEK-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 239000012930 cell culture fluid Substances 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000011210 chromatographic step Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 210000002706 plastid Anatomy 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 238000005001 rutherford backscattering spectroscopy Methods 0.000 description 4
- 238000010008 shearing Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 101800000263 Acidic protein Proteins 0.000 description 3
- 241000589151 Azotobacter Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 238000012424 Freeze-thaw process Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 239000012480 LAL reagent Substances 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002274 Nalgene Polymers 0.000 description 3
- 101710112672 Probable tape measure protein Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241001135311 Pseudoalteromonas nigrifaciens Species 0.000 description 3
- 241000589537 Pseudomonas marginalis Species 0.000 description 3
- 241000589776 Pseudomonas putida Species 0.000 description 3
- 238000001190 Q-PCR Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 101710204224 Tape measure protein Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000011035 continuous diafiltration Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 229960004198 guanidine Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000726119 Acidovorax Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000589154 Azotobacter group Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241001600125 Delftia acidovorans Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 108010054278 Lac Repressors Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001478324 Liberibacter Species 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 2
- 108010065338 N-ethylglycine Proteins 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241001505483 Plasmodium falciparum 3D7 Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
- 241000157890 Pseudoalteromonas piscicida Species 0.000 description 2
- 241000218935 Pseudomonas azotoformans Species 0.000 description 2
- 241000620655 Pseudomonas brenneri Species 0.000 description 2
- 241000180027 Pseudomonas cedrina Species 0.000 description 2
- 241000429405 Pseudomonas extremorientalis Species 0.000 description 2
- 241001312498 Pseudomonas gessardii Species 0.000 description 2
- 241001277052 Pseudomonas libanensis Species 0.000 description 2
- 241001277679 Pseudomonas mandelii Species 0.000 description 2
- 241001312486 Pseudomonas migulae Species 0.000 description 2
- 241000204709 Pseudomonas mucidolens Species 0.000 description 2
- 241000204735 Pseudomonas nitroreducens Species 0.000 description 2
- 241001291513 Pseudomonas orientalis Species 0.000 description 2
- 241001291486 Pseudomonas rhodesiae Species 0.000 description 2
- 241000589614 Pseudomonas stutzeri Species 0.000 description 2
- 241000218902 Pseudomonas synxantha Species 0.000 description 2
- 241001148199 Pseudomonas tolaasii Species 0.000 description 2
- 241001291485 Pseudomonas veronii Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000863432 Shewanella putrefaciens Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001818 capillary gel electrophoresis Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 108010038082 heparin proteoglycan Proteins 0.000 description 2
- 239000013628 high molecular weight specie Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- TWXDDNPPQUTEOV-UHFFFAOYSA-N hydron;n-methyl-1-phenylpropan-2-amine;chloride Chemical group Cl.CNC(C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000006713 insertion reaction Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 229940124735 malaria vaccine Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000006151 minimal media Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012529 ultrafiltration/diafiltration (UF/DF) membrane Substances 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- AEELXMHQIJJMKP-DMTCNVIQSA-N (2r,3s)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@@H](S)CO AEELXMHQIJJMKP-DMTCNVIQSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- RRWZZMHRVSMLCT-UHFFFAOYSA-N 2-(butylazaniumyl)acetate Chemical group CCCCNCC(O)=O RRWZZMHRVSMLCT-UHFFFAOYSA-N 0.000 description 1
- DRMDGQXVYQXMFW-UHFFFAOYSA-N 2-(ethylamino)butanedioic acid Chemical compound CCNC(C(O)=O)CC(O)=O DRMDGQXVYQXMFW-UHFFFAOYSA-N 0.000 description 1
- AHLFJIALFLSDAQ-UHFFFAOYSA-N 2-(pentylazaniumyl)acetate Chemical compound CCCCCNCC(O)=O AHLFJIALFLSDAQ-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- KCKPRRSVCFWDPX-UHFFFAOYSA-N 2-[methyl(pentyl)amino]acetic acid Chemical compound CCCCCN(C)CC(O)=O KCKPRRSVCFWDPX-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241001478307 Acidomonas Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001430273 Aminobacter Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241001626906 Blastomonas Species 0.000 description 1
- 241000131407 Brevundimonas Species 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000132069 Carica monoica Species 0.000 description 1
- 235000014649 Carica monoica Nutrition 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 241000863387 Cellvibrio Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000589519 Comamonas Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001670044 Curvibacter lanceolatus Species 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001528534 Ensifer Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241001670062 Halomonas utahensis Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241001660422 Herbaspirillum huttiense Species 0.000 description 1
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 1
- 241000216643 Hydrogenophaga Species 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001148466 Janthinobacterium lividum Species 0.000 description 1
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241001670047 Malikia spinosa Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000589350 Methylobacter Species 0.000 description 1
- 241001264650 Methylocaldum Species 0.000 description 1
- 241000589345 Methylococcus Species 0.000 description 1
- 241001533203 Methylomicrobium Species 0.000 description 1
- 241000321843 Methylosarcina Species 0.000 description 1
- 241000530467 Methylosphaera Species 0.000 description 1
- 241001670070 Microbulbifer elongatus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000625726 Oceanimonas Species 0.000 description 1
- 241000293010 Oligella Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241001670033 Phaseolibacter flectens Species 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 241000590028 Pseudoalteromonas haloplanktis Species 0.000 description 1
- 241000947836 Pseudomonadaceae Species 0.000 description 1
- 241000028636 Pseudomonas abietaniphila Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000168225 Pseudomonas alcaligenes Species 0.000 description 1
- 241001459308 Pseudomonas alcaliphila Species 0.000 description 1
- 241001522136 Pseudomonas alginovora Species 0.000 description 1
- 241000218934 Pseudomonas amygdali Species 0.000 description 1
- 241001325442 Pseudomonas andersonii Species 0.000 description 1
- 241000520869 Pseudomonas anguilliseptica Species 0.000 description 1
- 241000520871 Pseudomonas asplenii Species 0.000 description 1
- 241000202216 Pseudomonas avellanae Species 0.000 description 1
- 241001279845 Pseudomonas balearica Species 0.000 description 1
- 241001660019 Pseudomonas borealis Species 0.000 description 1
- 241000226031 Pseudomonas brassicacearum Species 0.000 description 1
- 241000204712 Pseudomonas caricapapayae Species 0.000 description 1
- 241001646398 Pseudomonas chlororaphis Species 0.000 description 1
- 241001670013 Pseudomonas chlororaphis subsp. aurantiaca Species 0.000 description 1
- 241001508466 Pseudomonas cichorii Species 0.000 description 1
- 241000520873 Pseudomonas citronellolis Species 0.000 description 1
- 241000647960 Pseudomonas coronafaciens pv. coronafaciens Species 0.000 description 1
- 241000168053 Pseudomonas denitrificans (nomen rejiciendum) Species 0.000 description 1
- 241000946440 Pseudomonas diterpeniphila Species 0.000 description 1
- 241000520898 Pseudomonas ficuserectae Species 0.000 description 1
- 241001148192 Pseudomonas flavescens Species 0.000 description 1
- 241000589538 Pseudomonas fragi Species 0.000 description 1
- 241001497665 Pseudomonas frederiksbergensis Species 0.000 description 1
- 241000490004 Pseudomonas fuscovaginae Species 0.000 description 1
- 241000231049 Pseudomonas gingeri Species 0.000 description 1
- 241000042121 Pseudomonas graminis Species 0.000 description 1
- 241000520899 Pseudomonas halodenitrificans Species 0.000 description 1
- 241001531427 Pseudomonas hydrogenovora Species 0.000 description 1
- 241001300822 Pseudomonas jessenii Species 0.000 description 1
- 241000913726 Pseudomonas kilonensis Species 0.000 description 1
- 241000357050 Pseudomonas lini Species 0.000 description 1
- 241001670039 Pseudomonas lundensis Species 0.000 description 1
- 241000218905 Pseudomonas luteola Species 0.000 description 1
- 241000145542 Pseudomonas marginata Species 0.000 description 1
- 241001670064 Pseudomonas meliae Species 0.000 description 1
- 241000589755 Pseudomonas mendocina Species 0.000 description 1
- 241001291501 Pseudomonas monteilii Species 0.000 description 1
- 241000589781 Pseudomonas oleovorans Species 0.000 description 1
- 241000218904 Pseudomonas oryzihabitans Species 0.000 description 1
- 241001670066 Pseudomonas pertucinogena Species 0.000 description 1
- 241001223182 Pseudomonas plecoglossicida Species 0.000 description 1
- 241000589630 Pseudomonas pseudoalcaligenes Species 0.000 description 1
- 241000530526 Pseudomonas psychrophila Species 0.000 description 1
- 241000231045 Pseudomonas reactans Species 0.000 description 1
- 241000520900 Pseudomonas resinovorans Species 0.000 description 1
- 241000218901 Pseudomonas straminea Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 241000218903 Pseudomonas taetrolens Species 0.000 description 1
- 241001478288 Pseudomonas thermocarboxydovorans Species 0.000 description 1
- 241000039935 Pseudomonas thermotolerans Species 0.000 description 1
- 241001669634 Pseudomonas thivervalensis Species 0.000 description 1
- 241000369631 Pseudomonas vancouverensis Species 0.000 description 1
- 241001464820 Pseudomonas viridiflava Species 0.000 description 1
- 241000577556 Pseudomonas wisconsinensis Species 0.000 description 1
- 241000039948 Pseudomonas xiamenensis Species 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001633102 Rhizobiaceae Species 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- QPKCPYHEBAZXOE-UHFFFAOYSA-N S(=O)(=O)(O)CS(=O)(=O)O.S1C=CC=CC=CC=C1 Chemical compound S(=O)(=O)(O)CS(=O)(=O)O.S1C=CC=CC=CC=C1 QPKCPYHEBAZXOE-UHFFFAOYSA-N 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241001135312 Sinorhizobium Species 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241001670040 Stenotrophomonas pictorum Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241000206217 Teredinibacter Species 0.000 description 1
- 241001670068 Thauera butanivorans Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241001670042 [Pseudomonas] boreopolis Species 0.000 description 1
- 241001670036 [Pseudomonas] cissicola Species 0.000 description 1
- 241001670030 [Pseudomonas] geniculata Species 0.000 description 1
- 241001670027 [Pseudomonas] hibiscicola Species 0.000 description 1
- KKKNAENNDRVRRC-UHFFFAOYSA-N [S].OCC(O)CO Chemical compound [S].OCC(O)CO KKKNAENNDRVRRC-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- CADZRPOVAQTAME-UHFFFAOYSA-L calcium;hydroxy phosphate Chemical compound [Ca+2].OOP([O-])([O-])=O CADZRPOVAQTAME-UHFFFAOYSA-L 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011188 deamidation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 101150112675 htpX gene Proteins 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009789 rate limiting process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200088010 rs63750664 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000012416 system suitability evaluation Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641105P | 2012-05-01 | 2012-05-01 | |
| US61/641,105 | 2012-05-01 | ||
| US13/844,261 | 2013-03-15 | ||
| US13/844,261 US9169304B2 (en) | 2012-05-01 | 2013-03-15 | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201348250A TW201348250A (zh) | 2013-12-01 |
| TWI630213B true TWI630213B (zh) | 2018-07-21 |
Family
ID=49514758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102115278A TWI630213B (zh) | 2012-05-01 | 2013-04-29 | 用於純化重組型惡性瘧原蟲（ｐｌａｓｍｏｄｉｕｍ ｆａｌｃｉｐａｒｕｍ）環孢子體蛋白質之方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9169304B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2844666B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6238967B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102087461B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104379596B (cg-RX-API-DMAC7.html) |
| AR (1) | AR090900A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013256757B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014027019B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2870198C (cg-RX-API-DMAC7.html) |
| MX (1) | MX352093B (cg-RX-API-DMAC7.html) |
| MY (1) | MY166380A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ630121A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201407108TA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI630213B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013165732A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201407420B (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| WO2015105551A1 (en) * | 2014-01-09 | 2015-07-16 | Kentucky Bioprocessing, Inc. | Method of purifying monoclonal antibodies |
| WO2015148943A1 (en) * | 2014-03-28 | 2015-10-01 | Conjugon, Inc. | Preparation of small colony variants of therapeutic bacteria |
| ES2952405T3 (es) | 2014-12-01 | 2023-10-31 | Pfenex Inc | Parejas de fusión para la producción de péptidos |
| CN109966319B (zh) * | 2017-12-22 | 2022-11-22 | 四川好医生攀西药业有限责任公司 | 一种康复新液的原料及其制备方法和应用 |
| CN108559721A (zh) * | 2018-05-15 | 2018-09-21 | 北京师范大学 | 一种净化空气的复合微生物菌剂及其应用 |
| EP4171630A1 (en) * | 2020-06-29 | 2023-05-03 | Path | Pre-erythrocytic malaria vaccines |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2145092B (en) | 1983-01-28 | 1988-04-07 | Univ New York | Protective peptide antigen |
| US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| CH660375A5 (it) | 1983-02-08 | 1987-04-15 | Sclavo Spa | Procedimento per la produzione di proteine correlate alla tossina difterica. |
| US4755465A (en) | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| US5281532A (en) | 1983-07-27 | 1994-01-25 | Mycogen Corporation | Pseudomas hosts transformed with bacillus endotoxin genes |
| US4830962A (en) | 1984-02-09 | 1989-05-16 | Cetus Corporation | Recombinant diphtheria toxin fragments |
| ZA855232B (en) | 1984-07-23 | 1986-02-26 | Univ New York | Protective peptide antigen corresponding to plasmodium falciparum circumsporozoite protein |
| US5178861A (en) | 1984-09-12 | 1993-01-12 | New York University | Cross-reactive and protective epitopes of circumsporozoite proteins |
| NZ213303A (en) | 1984-09-12 | 1988-09-29 | Univ New York | Plasmodium protein, dna sequence and vaccine |
| US4695455A (en) | 1985-01-22 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of pesticides produced by expression of heterologous genes |
| US4695462A (en) | 1985-06-28 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of biological pesticides |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| GB8517071D0 (en) | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
| ATE118784T1 (de) | 1985-07-12 | 1995-03-15 | Univ New York | Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen. |
| CA1340373C (en) | 1986-01-28 | 1999-02-02 | Rino Rappuoli | Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin |
| EP0252588A3 (en) | 1986-05-12 | 1989-07-12 | Smithkline Beecham Corporation | Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| WO1988005817A1 (en) | 1987-01-30 | 1988-08-11 | Smith Kline - Rit S.A. | Expression of the p. falciparum circumsporozoite protein by yeast |
| JP2918895B2 (ja) | 1987-09-04 | 1999-07-12 | アムジエン・インコーポレーテツド | 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体 |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5128130A (en) | 1988-01-22 | 1992-07-07 | Mycogen Corporation | Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens |
| AU625713B2 (en) | 1988-02-19 | 1992-07-16 | Microgenesys, Inc. | Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum |
| US5055294A (en) | 1988-03-03 | 1991-10-08 | Mycogen Corporation | Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens |
| GB8812214D0 (en) | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| US5028425A (en) | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
| DE68927933T2 (de) * | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US6043057A (en) | 1988-09-16 | 2000-03-28 | Vitec Aktiebolag | Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP0409923A4 (en) | 1988-12-21 | 1993-01-20 | Smithkline Biologicals | Expression of the i(plasmodium) circumsporozoite protein in insect cells |
| WO1990009444A1 (en) | 1989-02-10 | 1990-08-23 | Genesit Oy | A method for producing pertussis toxin subunits |
| US7232671B2 (en) | 1989-02-15 | 2007-06-19 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
| NZ233255A (en) | 1989-04-11 | 1993-02-25 | Chiron Corp | Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope |
| DK0396964T3 (da) | 1989-04-28 | 1995-10-30 | Sclavo Spa | Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner |
| GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
| US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
| ATE93271T1 (de) | 1989-11-28 | 1993-09-15 | Wellcome Found | Vakzine. |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| AU1762092A (en) | 1991-04-01 | 1992-11-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria |
| US5935580A (en) | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| EP0616034B1 (en) | 1993-03-05 | 2004-10-20 | Wyeth Holdings Corporation | Plasmid for production of CRM protein and diphtheria toxin |
| EP0725653B2 (en) | 1993-10-05 | 2008-04-02 | UCB Pharma Limited | Vaccine compositions |
| GB9406492D0 (en) | 1994-03-31 | 1994-05-25 | Isis Innovation | Malaria peptides |
| US20040214157A1 (en) | 1994-06-29 | 2004-10-28 | Simon C. Burton | Chromatographic resins and methods for using same |
| US5652348A (en) | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| US5932714A (en) | 1995-02-23 | 1999-08-03 | Connaught Laboratories Limited | Expression of gene products from genetically manipulated strains of Bordetella |
| SE9600590D0 (sv) | 1996-02-19 | 1996-02-19 | Pharmacia Biotech Ab | Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris |
| GB9616351D0 (en) | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
| WO1998012332A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| US7393630B2 (en) | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
| CA2359610A1 (en) | 1999-02-18 | 2000-08-24 | Rmf Dictagene S.A. | Malaria vaccine |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
| AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| US7781186B2 (en) | 2000-09-25 | 2010-08-24 | The United States Of America As Represented By The Secretary Of The Army | Screening methods using normal human liver cell line |
| AU2001293074A1 (en) | 2000-09-25 | 2002-04-08 | Walter Reed Army Institute Of Research | Human liver cell line |
| US7363166B2 (en) * | 2001-03-30 | 2008-04-22 | Council Of Scientific & Industrial Research | Computational method for the identification of candidate proteins useful as anti-infectives |
| SE0104353D0 (sv) | 2001-12-19 | 2001-12-19 | Amersham Biosciences Ab | Separation method |
| WO2004041857A2 (en) | 2002-06-17 | 2004-05-21 | Ballard Jimmy D | Mutant of clostridium difficile toxin b and methods of use |
| US20040067880A1 (en) | 2002-10-04 | 2004-04-08 | Kuo Macus Tien | Prodrug therapy of liver diseases using receptor-mediated delivery of malarial circumsporozoite protein as a carrier |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| ES2594758T3 (es) | 2002-10-23 | 2016-12-22 | Glaxosmithkline Biologicals S.A. | Procedimientos de vacunación contra la malaria |
| CA2507915C (en) | 2002-12-17 | 2013-07-02 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| US7670631B2 (en) | 2003-03-12 | 2010-03-02 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists |
| US8399217B2 (en) | 2003-03-14 | 2013-03-19 | Brookhaven Science Associates, Llc | High density growth of T7 expression strains with auto-induction option |
| JP5087741B2 (ja) | 2003-11-19 | 2012-12-05 | フェネックス インコーポレイテッド | 改良タンパク質発現系 |
| EP1687324B1 (en) | 2003-11-21 | 2012-08-22 | Pfenex, Inc. | Improved expression systems with sec-system secretion |
| WO2005063805A1 (en) | 2003-12-23 | 2005-07-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection |
| JP5602336B2 (ja) | 2004-01-16 | 2014-10-08 | フェネックス インコーポレイテッド | シュードモナス・フルオレッセンスにおける哺乳動物タンパク質の発現 |
| EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
| AU2005277463A1 (en) | 2004-08-20 | 2006-03-02 | Kmt Hepatech, Inc. | Malarial animal model having a chimeric human liver |
| GB0420634D0 (en) | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
| AU2006214694B2 (en) | 2005-01-18 | 2011-09-08 | Walter Reed Army Institute Of Research | A plasmodium vivax hybrid circumsporozoite protein and vaccine |
| EP1754717A1 (en) | 2005-08-19 | 2007-02-21 | Université de Lausanne | Antigenic peptides and their use |
| BRPI0616602A2 (pt) | 2005-09-30 | 2011-06-28 | Seattle Biomedical Res Inst | polipeptìdeo isolado, composição imunogênica, molécula de ácido nucleico isolada, e, uso de uma composição imunogênica |
| US7749519B2 (en) | 2005-12-09 | 2010-07-06 | Kim Lee Sim | Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax |
| US20070292918A1 (en) | 2006-05-30 | 2007-12-20 | Stelman Steven J | Codon optimization method |
| AU2008210538B2 (en) | 2007-01-31 | 2013-06-06 | Pelican Technology Holdings, Inc. | Bacterial leader sequences for increased expression |
| EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CL2008002361A1 (es) | 2007-08-13 | 2009-08-07 | Glaxosmithkline Biologicals Sa | Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria. |
| WO2009114202A2 (en) | 2008-03-14 | 2009-09-17 | The United States Of America As Represented By The Secretary Of The Navy | Vaccine and immunization method using plasmodium antigen 2 |
| WO2010008764A1 (en) | 2008-06-23 | 2010-01-21 | Dow Global Technologies Inc. | Pseudomonas fluorescens strains for production of extracellular recombinant protein |
| WO2010051360A1 (en) | 2008-10-31 | 2010-05-06 | Wyeth Llc | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| US8063193B2 (en) | 2009-03-27 | 2011-11-22 | Abbott Laboratories | Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof |
| ES2639398T3 (es) | 2010-03-04 | 2017-10-26 | Pfenex Inc. | Método para producir proteína de interferón recombinante soluble sin desnaturalización |
| KR20130072201A (ko) | 2010-03-30 | 2013-07-01 | 피페넥스 인크. | 재조합 독소 단백질의 고수준 발현 |
| WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| DK2385107T3 (en) * | 2010-05-03 | 2016-12-12 | Pasteur Institut | Lentiviral vector-based immunological compounds against malaria |
| WO2012154199A1 (en) | 2010-10-18 | 2012-11-15 | The Government Of The United States, As Represented By The Secretary Of The Army | Soluble recombinant plasmodium falciparum circumsporozoite protein |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
-
2013
- 2013-03-15 US US13/844,261 patent/US9169304B2/en active Active
- 2013-04-22 NZ NZ630121A patent/NZ630121A/en not_active IP Right Cessation
- 2013-04-22 WO PCT/US2013/037656 patent/WO2013165732A1/en not_active Ceased
- 2013-04-22 BR BR112014027019-8A patent/BR112014027019B1/pt active IP Right Grant
- 2013-04-22 JP JP2015510319A patent/JP6238967B2/ja active Active
- 2013-04-22 SG SG11201407108TA patent/SG11201407108TA/en unknown
- 2013-04-22 EP EP13784680.4A patent/EP2844666B1/en active Active
- 2013-04-22 AU AU2013256757A patent/AU2013256757B2/en not_active Ceased
- 2013-04-22 CN CN201380033337.6A patent/CN104379596B/zh not_active Expired - Fee Related
- 2013-04-22 KR KR1020147033423A patent/KR102087461B1/ko active Active
- 2013-04-22 MX MX2014013124A patent/MX352093B/es active IP Right Grant
- 2013-04-22 CA CA2870198A patent/CA2870198C/en active Active
- 2013-04-22 MY MYPI2014003077A patent/MY166380A/en unknown
- 2013-04-29 TW TW102115278A patent/TWI630213B/zh not_active IP Right Cessation
- 2013-04-30 AR ARP130101473A patent/AR090900A1/es not_active Application Discontinuation
-
2014
- 2014-10-14 ZA ZA2014/07420A patent/ZA201407420B/en unknown
-
2015
- 2015-09-01 US US14/842,672 patent/US9849177B2/en active Active
Non-Patent Citations (5)
Also Published As
| Publication number | Publication date |
|---|---|
| US20160051677A1 (en) | 2016-02-25 |
| EP2844666A4 (en) | 2015-11-04 |
| EP2844666B1 (en) | 2019-07-17 |
| MX352093B (es) | 2017-11-08 |
| AU2013256757A1 (en) | 2014-10-30 |
| TW201348250A (zh) | 2013-12-01 |
| KR102087461B1 (ko) | 2020-03-10 |
| BR112014027019A2 (pt) | 2017-07-11 |
| CN104379596B (zh) | 2018-05-29 |
| BR112014027019B1 (pt) | 2022-09-06 |
| WO2013165732A1 (en) | 2013-11-07 |
| MY166380A (en) | 2018-06-25 |
| CA2870198A1 (en) | 2013-11-07 |
| US9169304B2 (en) | 2015-10-27 |
| CN104379596A (zh) | 2015-02-25 |
| US20140051841A1 (en) | 2014-02-20 |
| AR090900A1 (es) | 2014-12-17 |
| JP2015517464A (ja) | 2015-06-22 |
| AU2013256757B2 (en) | 2017-02-16 |
| MX2014013124A (es) | 2015-02-05 |
| ZA201407420B (en) | 2016-10-26 |
| US9849177B2 (en) | 2017-12-26 |
| NZ630121A (en) | 2016-06-24 |
| KR20150027743A (ko) | 2015-03-12 |
| SG11201407108TA (en) | 2014-11-27 |
| CA2870198C (en) | 2019-12-03 |
| JP6238967B2 (ja) | 2017-11-29 |
| EP2844666A1 (en) | 2015-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI630213B (zh) | 用於純化重組型惡性瘧原蟲（ｐｌａｓｍｏｄｉｕｍ ｆａｌｃｉｐａｒｕｍ）環孢子體蛋白質之方法 | |
| JP7148579B2 (ja) | ペプチド産生のための融合パートナー | |
| CA2220447C (en) | Novel fusion protein recovery and purification methods | |
| ES2688065T5 (es) | Métodos y sistemas para purificar la neurotoxina botulínica no complejada | |
| JP2006517415A5 (cg-RX-API-DMAC7.html) | ||
| JP2016515396A (ja) | ペプチドおよびタンパク質の発現のための方法 | |
| JPS63501471A (ja) | インタ−フェロンの精製方法 | |
| CA2206848A1 (en) | Production of peptides using recombinant fusion protein constructs | |
| US20160002287A1 (en) | High ph protein refolding methods | |
| KR20220061126A (ko) | 카스파제-2 변이체 | |
| Gautam et al. | Non-chromatographic strategies for protein refolding | |
| JP2001512745A (ja) | インスリンｃ−ペプチドの組換え発現 | |
| EP3374376B1 (en) | Industrially scalable process for recovering biologically active recombinant carrier proteins | |
| JP4088584B2 (ja) | 融合タンパク質から目的タンパク質を分離する方法。 | |
| US9580488B2 (en) | Fusion tags and expression vector system for the expression of human parathyroid hormone (rhPTH) | |
| US20030077692A1 (en) | Refolding method | |
| Asante-Appiah et al. | Purification of untagged retroviral integrases by immobilized metal ion affinity chromatography | |
| WO2008024311A2 (en) | Purification of low-abundant recombinant proteins from cell culture | |
| WO2022263559A1 (en) | Production of cross-reactive material 197 fusion proteins | |
| JPH0724596B2 (ja) | インタ−フェロンの精製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |